Physician profile
Ari Daniel Abel
NPI 1932153293
$1,375.87
in general payments reported to CMS, 2019-2025
19 companies · $72.53 in 2025
The $72.53 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $36.90 · 2021: $179 · 2022: $250 · 2023: $266 · 2024: $356 · 2025: $72.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $203.72 | 2021-2025 | Acthar |
| Alcon Vision LLC | $155.58 | 2021-2024 | Rocklatan, Hydrus Microstent |
| Abbvie INC. | $146.93 | 2023-2024 | Lumigan, Xen Glaucoma Treatment System |
| Galderma Laboratories, L.P. | $142.93 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $120.58 | 2020-2024 | Cequa |
| Bausch & Lomb Americas INC. | $101.43 | 2022-2024 | Vyzulta, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.40 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $77.18 | 2019-2021 | |
| Horizon Therapeutics Plc | $61.67 | 2019-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $59.44 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $58.02 | 2023 | Istent Inject Trabecular Micro-Bypass System, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Merz Pharmaceuticals, LLC | $30.68 | 2024 | Xeomin |
| Oyster Point Pharma, INC. | $28.25 | 2022 | |
| Biotissue Holdings INC. | $19.75 | 2025 | |
| Ani Pharmaceuticals, INC. | $17.33 | 2024 | Purified Cortrophin Gel |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $17.06 | 2024 | Ilevro |
| Thea Pharma INC. | $16.23 | 2024 | Iyuzeh |
| Amgen INC. | $13.54 | 2024 | Tepezza |
| Allergan, INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Abel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.